Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) EBITDA (2024 - 2025)

Allarity Therapeutics' EBITDA history spans 2 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 70.61% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$11.9 million, up 51.36%, while the annual FY2025 figure was -$11.9 million, 51.35% up from the prior year.
  • EBITDA reached -$2.1 million in Q4 2025 per ALLR's latest filing, up from -$2.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.8 million in Q2 2024 to a low of -$11.8 million in Q3 2024.